RxDoctor Payments Data

Robert Audycki

Corneal and Contact Management · N Dartmouth, MANPI 1689673428

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 27.3% of the total. That places this record below the midpoint for corneal and contact management clinicians in MA, where the typical reported total is $587.

$587in general payments, 2019–2025

Across 16 payments — averaging $36.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$161
  • Coopervision Inc.$155
  • Carl Zeiss Meditec, Inc.$56
  • Menicon America Inc$53
  • Alcon$44
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$36
  • plus $82 from 4 others

What the payments were for

  • Food & beverage$587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$587 in reported general payments places this provider in the 50th percentile of 30 corneal and contact management providers in Massachusetts.

See all corneal and contact management providers in Massachusetts

Medicare billing

Part B allowed, 2024
$97,897
Medicare patients
617
Services billed
947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine17$12,672
Prednisolone Acetate29$896
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha34$334
Ofloxacin23$308
ErythromycinErythromycin Base15$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$14$12,67217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 30 corneal and contact management providers in Massachusetts.

Other corneal and contact management in N Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →